Loading...
Market
What will be HilleVax's stock price range by the end of 2024?
3
Resolution / Starting Odds
Below $1 • 25%
$1 to $2 • 25%
$2 to $5 • 25%
Above $5 • 25%
Publicly available stock market data
Story
HilleVax Shares Plunge 88.6% to $1.60 After Norovirus Vaccine Fails in Mid-Stage Trial
Jul 8, 2024, 01:50 PM
HilleVax reported that its NEST-IN1 Phase 2b clinical study of HIL-214 in infants did not meet its primary or secondary efficacy endpoints. As a result, the company will discontinue further development of HIL-214 in infants. Following this announcement, HilleVax's stock plummeted, dropping 88.6% to $1.60 in premarket trade, with an 86.3% decline premarket. The failed trial aimed to prevent gastroenteritis caused by norovirus, specifically acute gastroenteritis. The significant decline in stock value reflects investor disappointment in the biotech company's sole clinical candidate's failure.
View original story
Similar markets
Below $100 • 25%
$100 to $120 • 25%
$120 to $140 • 25%
Above $140 • 25%
Below $50 • 25%
$50-$74.99 • 25%
$75-$99.99 • 25%
$100 or higher • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
Above $40 • 25%
Less than €5 billion • 25%
€5 billion to €6 billion • 25%
€6 billion to €7 billion • 25%
More than €7 billion • 25%
Below $100 • 25%
$100 - $150 • 25%
$150 - $200 • 25%
Above $200 • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Below $166 • 33%
$166 to $213 • 33%
Above $213 • 34%
Increased by more than 50% • 25%
Increased by 25% to 50% • 25%
Increased by less than 25% • 25%
Decreased • 25%